Trends in Hepatocellular Carcinoma among Hepatitis C Patients Achieving Sustained Virological Response Following Direct-Acting Antivirals Treatment
),
(1) Fellows of the Indonesian Society of Internal Medicine; Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine Universitas Airlangga/Dr. Soetomo Hospital, Surabaya
Corresponding Author
Abstract
References
Fiehn F, Beisel C, Binder M. Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals. Curr Opin Virol. 2024;67:101423. doi:10.1016/j.coviro.2024.101423
World Health Organization. Global Hepatitis Report 2024 Action for Access in Low- and Middle-Income Countries. World Health Organization; 2024.
Spengler U. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018;183:118-126. doi:10.1016/j.pharmthera.2017.10.009
Hashim A, Almahdi F, Albaba EA, et al. Efficacy of DAAs in the Treatment of Chronic HCV: Real-World Data from the Private Health-Care Sector of the Kingdom of Saudi Arabia. J Epidemiol Glob Health. 2020;10(2):178. doi:10.2991/jegh.k.200117.002
Ahn YH, Lee H, Kim DY, et al. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C. Gut Liver. 2021;15(3):410-419. doi:10.5009/gnl20151
Alarfaj SJ, Alzahrani A, Alotaibi A, et al. The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia. Saudi Pharm J. 2022;30(10):1448-1453. doi:10.1016/j.jsps.2022.07.005
Ali H, Vikash F, Moond V, et al. Global trends in hepatitis C-related hepatocellular carcinoma mortality: A public database analysis (1999-2019). World J Virol. 2024;13(1). doi:10.5501/wjv.v13.i1.89469
Muzica CM, Stanciu C, Huiban L, et al. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. World J Gastroenterol. 2020;26(43):6770-6781. doi:10.3748/wjg.v26.i43.6770
Chan PPY, Levy MT, Shackel N, Davison SA, Prakoso E. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. Hepatobiliary Pancreat Dis Int. 2020;19(6):541-546. doi:10.1016/j.hbpd.2020.06.013
Rinaldi L, Nevola R, Franci G, et al. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers (Basel). 2020;12(6):1351. doi:10.3390/cancers12061351
El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016;64(1):130-137. doi:10.1002/hep.28535
Lv GJ, Ji D, Yu L, et al. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis. Hepatol Int. 2024;18(5):1459-1471. doi:10.1007/s12072-024-10700-7
Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DTY. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol. 2022;28(1):96-107. doi:10.3748/wjg.v28.i1.96
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C.; 2023. www.hcvguidelines.org
Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther. 2022;22(6):621-632. doi:10.1080/14737140.2022.2074404
Shiha G, Mousa N, Soliman R, NNH Mikhail N, Adel Elbasiony M, Khattab M. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. J Viral Hepat. 2020;27(7):671-679. doi:10.1111/jvh.13276
Article Metrics
Abstract View
: 43 times
Download : 7 times
DOI: 10.24871/25320241-2
Refbacks
- There are currently no refbacks.
